Frequent inactivation of Cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines

Clinical Cancer Research

Volumn 19, Issue 12, 2013, Pages 3201-3211

  Jeschke, Jana ^a,c   O'Hagan, Heather M ^a   Zhang, Wei ^a   Vatapalli, Rajita ^a   Calmon, Marilia Freitas ^a   Danilova, Ludmila ^a   Nelkenbrecher, Claudia ^c   Van Neste, Leander ^d   Bijsmans, Ingrid T G W ^e   Van Engeland, Manon ^e   Gabrielson, Edward ^b   Schuebel, Kornel E ^a   Winterpacht, Andreas ^c   Baylin, Stephen B ^a   Herman, James G ^a   Ahuja, Nita ^a,f  

^a Department of Surgery ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d MDxHealth   (Belgium)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AZACITIDINE; CYSTEINE DIOXYGENASE; CYSTEINE DIOXYGENASE 1; DNA; DOXORUBICIN; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CHROMATIN STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DETOXIFICATION; DNA METHYLATION; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; EPIGENETICS; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OXIDATIVE STRESS; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEFECT; PROTEIN EXPRESSION;

ANTHRACYCLINES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYSTEINE DIOXYGENASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; REACTIVE OXYGEN SPECIES;

EID: 84879493961     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3751     Document Type: Article

References (40)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
2. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2:S4-11.
3. Glockner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009;69:4691-9.
4. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007;3:1709-23.
5. Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008;68:2764-72.
6. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 2011;71:2988-99.
7. Jeschke J, Van Neste L, Glockner SC, Dhir M, Calmon MF, Deregowski V, et al. Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 2012;7:701-9.
8. Joseph CA, Maroney MJ. Cysteine dioxygenase: structure and mechanism. Chem Commun 2007:3338-49.
9. Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. FEMS Microbiol Lett 2003;226:195-202.
10. Stipanuk MH, Ueki I, Dominy JE Jr, Simmons CR, Hirschberger LL. Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels. Amino Acids 2009;37:55-63.
11. Bradley H, Gough A, Sokhi RS, Hassell A, Waring R, Emery P. Sulfate metabolism is abnormal in patients with rheumatoid arthritis. Confirmation by in vivo biochemical findings. J Rheumatol 1994;21:1192-6.
12. Gordon C, Bradley H, Waring RH, Emery P. Abnormal sulphur oxidation in systemic lupus erythematosus. Lancet 1992;339:25-6.
13. Heafield MT, Fearn S, Steventon GB, Waring RH, WilliamsAC, Sturman SG. Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease. Neurosci Lett 1990;110:216-20.
14. Maschietto M, Piccoli FS, Costa CM, Camargo LP, Neves JI, Grundy PE, et al. Gene expression analysis of blastemal component reveals genes associated with relapse mechanism in Wilms tumour. Eur J Cancer 2011;47:2715-22.
15. Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, et al. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients. BMC Cancer 2010;10:247.
16. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004;118:781-94.
17. Dominy JE Jr, Hwang J, Stipanuk MH. Overexpression of cysteine dioxygenase reduces intracellular cysteine and glutathione pools in HepG2/C3A cells. Am J Physiol Endocrinol Metab 2007;293:E62-9.
18. Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J, Cheng X. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 2004;64: 4577-84.
19. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 2000;59:163-70.
20. Oltra AM, Carbonell F, Tormos C, Iradi A, Saez GT. Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med 2001;30:1286-92.
21. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Selective killing of oncogenically transformed cells through a ROSmediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006;10:241-52.
22. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003;31:1441-4.
23. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006;25:695-705.
24. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004;7:97-110.
25. Fruehauf JP, Meyskens FL Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res 2007;13:789-94.
26. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006;10:175-6.
27. Trachootham D, Alexandre J, Huang P. Targeting cancer cells byROSmediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-91.
28. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552-6.
29. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
30. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002;62:7213-8.
31. Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste L, et al. DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res 2012;40:4334-46.
32. Ye S, Wu X, Wei L, Tang D, Sun P, Bartlam M, et al. An insight into the mechanism of human cysteine dioxygenase. Key roles of the thioetherbonded tyrosine-cysteine cofactor. J Biol Chem 2007;282:3391-402.
33. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979;254:7558-60.
34. Mossman D, Scott RJ. Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation. PLoS ONE 2011;6: e23127.
35. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006;66: 7490-501.
36. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, et al. Genome-wide mapsof chromatin state in pluripotent and lineagecommitted cells. Nature 2007;448:553-60.
37. Schneider BL, Kulesz-Martin M. Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. Carcinogenesis 2004;25:2033-44.
38. Martinez-Sanchez G, Giuliani A. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development. J Exp Clin Cancer Res 2007;26:39-50.
39. Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A, et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007;67:1472-86.
40. De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012;21:655-67.